<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:media="http://search.yahoo.com/mrss/"
	>

<channel>
	<title>Adam Bluestein</title>
	<link>https://adambluestein.com</link>
	<description>Adam Bluestein</description>
	<pubDate>Mon, 24 Jul 2017 19:47:51 +0000</pubDate>
	<generator>https://adambluestein.com</generator>
	<language>en</language>
	
		
	<item>
		<title>Contact</title>
				
		<link>http://adambluestein.com/Contact</link>

		<comments></comments>

		<pubDate>Mon, 24 Jul 2017 19:47:51 +0000</pubDate>

		<dc:creator>Adam Bluestein</dc:creator>
		
		<category><![CDATA[]]></category>

		<guid isPermaLink="false">197737</guid>

		<description>Adam BluesteinLet’s ConnectThe best way to reach me is via email: adambluestein@gmail.com. I am also on LinkedIn.&#38;nbsp;I am happy to read relevant pitches and tips from companies, publicists, and individuals. (See my Selected Work page to get a sense of the subjects that interest me.) Because of the volume of email I receive, I cannot respond to everything personally. But feel free to follow up if you think I’ve missed something important!I also welcome inquiries about teaching, public speaking, and other collaborative endeavors.
&#38;nbsp;
</description>
		
		<excerpt>Adam BluesteinLet’s ConnectThe best way to reach me is via email: adambluestein@gmail.com. I am also on LinkedIn.&#38;nbsp;I am happy to read relevant pitches and...</excerpt>

		<!--<wfw:commentRss></wfw:commentRss>-->

	</item>
		
		
	<item>
		<title>Selected Work</title>
				
		<link>http://adambluestein.com/Selected-Work</link>

		<comments></comments>

		<pubDate>Mon, 24 Jul 2017 19:47:40 +0000</pubDate>

		<dc:creator>Adam Bluestein</dc:creator>
		
		<category><![CDATA[]]></category>

		<guid isPermaLink="false">197736</guid>

		<description>Adam Bluestein
Selected Work
“This company’s drug could effectively end the HIV epidemic—but patients remember how it slow-walked a past treatment.” Print feature on the development of Gilead Sciences’ groundbreaking PrEP shot, lenacapavir.&#38;nbsp;Fast Company, June 2025“How the federal government is tracking changes in the supply of street drugs.” Scientsts at the National Institute of Standards and Technology’s are using advance analysis to prevent overdoses and reduce dangerous side effects of illicit drug ingredients.&#38;nbsp; MIT Technology Review, April 2025
“Phineas and Ferb are making a mischievous return, targeting multiple generations of fans.” I spoke with the creators of Disney’s hit animated series and company execs about the show’s long-awaited comeback. Fast Company, April 2025“How to Focus Like Your Life Depends On It.” Formula 1 driver Oscar Piastri and others share strategies for paying attention on course and in life.&#38;nbsp;New York Times, November 2024 &#38;nbsp;
“This startup is building the country’s most powerful quantum computer on Chicago’s South Side.” How PsiQuantum emerged as a leader in the race to build a utility-scale quantum computer. Fast Company, July 2024

“Ozempic for Everyone? Inside Novo Nordisk’s Big Plans for Its Weight-Loss Drugs.”&#38;nbsp;How the Danish diabetes specialist shifted gears and targeted the U.S. market with its GLP-1 blockbusters. Fast Company, December 2023
“Moderna became a hero with its COVID-19 vaccine—now comes the hard part.” Profile of pandemic darling and mRNA pioneer and its efforts to deliver new treatments. Fast Company, June 2023

“The Lock-Picker, the Lockmaker, and the Odyssey to Expose a Major Security Flaw.” Ethical hackers take on the security industry. Bloomberg Businessweek,&#38;nbsp;December 2021

“How Mormons Built the Next Silicon Valley While No One Was Looking.” How LDS religious values infusing Utah’s&#38;nbsp; blazing-hot tech scene. As businesses seek to lure outsiders, does that need to change? Marker,&#38;nbsp;January 2020
“Flower Power.” How Mikey Steinmetz, CEO and cofounder of craft-grown cannabis distributor Flow Kana, is helping multi-generation Emerald Triangle growers weather the storms of legalization.&#38;nbsp;Men’s Journal,&#38;nbsp;January/February 2020“After a Comeback, 23andMe Faces Its Next Test.” Profile of Anne Wojcicki, CEO of the pioneering consumer genomics company.&#38;nbsp;Fast Company, September 2017</description>
		
		<excerpt>Adam Bluestein Selected Work “This company’s drug could effectively end the HIV epidemic—but patients remember how it slow-walked a past treatment.” Print...</excerpt>

		<!--<wfw:commentRss></wfw:commentRss>-->

	</item>
		
		
	<item>
		<title>Home Page</title>
				
		<link>http://adambluestein.com/Home-Page</link>

		<comments></comments>

		<pubDate>Mon, 17 Aug 2015 23:34:03 +0000</pubDate>

		<dc:creator>Adam Bluestein</dc:creator>
		
		<category><![CDATA[]]></category>

		<guid isPermaLink="false">197732</guid>

		<description>Adam BluesteinAs a contributor to publications including Fast Company, Fortune, Bloomberg Businessweek, Inc., Men’s Journal, and the New York Times,&#38;nbsp;I write about people and companies at the forefront of innovation in business, science, technology, and the creative economy. I am inspired by opportunities to dive into a complex subject, find the experts to help me truly understand it, and create accessible work that informs and inspires readers.As a speaker and moderator, I have appeared onstage at international business and tech conferences including WebSummit, Collision, Slush, TechBBQ, Biotech Showcase, and the Global Quantum Forum.&#38;nbsp;

I also work with entrepreneurs, startups, and organizations to help them craft authentic and compelling stories for media, customers, investors, and employees. With Keurig Green Mountain founder Bob Stiller,  I co-wrote Better &#38;amp; Better, an inspirational book on building a high-engagement business culture, published by McGraw Hill in September 2024.&#38;nbsp; 
 Selected work&#38;nbsp; Contact&#38;nbsp;
 LinkedIn
</description>
		
		<excerpt>Adam BluesteinAs a contributor to publications including Fast Company, Fortune, Bloomberg Businessweek, Inc., Men’s Journal, and the New York Times,&#38;nbsp;I write...</excerpt>

		<!--<wfw:commentRss></wfw:commentRss>-->

	</item>
		
	</channel>
</rss>